28th International Conference on Cancer Research and Pharmacology



PULSUS Conferences is glad to invite all the participants across the globe to attend 28th International Conference on Cancer Research and Pharmacology” scheduled during June 29-30, 2020  in Paris, France  which will mark the gathering of many renowned Oncologists, Pharmacologists, Healthcare Professionals, Researchers, Academicians, Students and Business Delegates. The meeting for this year will revolve around the theme “Conquering Cancer with the Modern progression”

 Conference Highlights: 

Track 2 : Organ Specific Cancer

Track 3 : Radiation Oncology

Track 4 : Neuro-Oncology

Track 5 : Cancer Immunotherapy

Track 6 : Innovation and Clinical Trials

Track 7 : Cancer Imaging and Early Detection

Track 8 : Cancer Screening and Diagnosis

Track 9 : Biology of Pediatric and Young Adult Cancer

Track 10 : Radiology and Imaging Technologies

Track 11 : DNA Damage, Mutation and Cancer

Track 12 : Cancer Nanotechnology

Track 13 : Cancer Epidemiology

Track 14 : Oncology Nursing Care

Track 15 : Cancer Nanomedicine

Track 16 : Cancer Prevention Vaccines

Track 17 : Pharmacology

Track 18 : Pharmacogenomics

Track 19 : Ethnopharmacology

Track 20 : Advances in Pharmacological Research

Track 21 : Pediatrics Pharmacology

Track 22 : Pharmacognosy

Track 23 : Drug screening and Discovery

Track 24 : Medical Toxicology

Track 25 : Therapeutic Innovation in Pharmacology


Track 26 : Clinical Research and Drug Legislation

Targeted Audience : 
Oncologists, Pharmacologists, Pharma Practitioners, Radiologists, Chemotherapists, Physicians, Academicians, Academic scientists, Industry professionals, Diagnostic laboratory professionals, Undergraduate & Postgraduate students, researchers, business professionals, Postdoctoral fellows and Trainees, Cancer Diagnostics Associations and Societies.
  



For contact :

Drop us an email for Program enquiry.
cancerresearch@pulsusseries.com
Sponsors / Exhibiting / Advertising.
cancer@pulsusmeet.com
sponsors@pulsus.com

Comments

Post a Comment

Popular posts from this blog

Image
Researchers have identified a targeted therapy for adolescent patients with neuroblastoma, a deadly pediatric nerve cancer, who would otherwise have no treatment options Neuroblastoma is one of the most common and aggressive pediatric nervous system tumors and generally has a poor prognosis, particularly when it advances in older children. Treatment success for the disease varies, but is exponentially less in adolescent patients, particularly because the disease lacks effective targeted therapies.  Scientists continue to expand this research into the role of the mutant ATRX protein in the laboratory and hope to eventually open a clinical trial with collaborating institutions. Based on this research, they believe that EZH2 inhibitors could also be effective in other ATRX mutant cancers, such as pediatric glioblastoma multiforme and osteosarcoma. Submit your research at  https://cancer.cmesociety.com/abstract-submission
Read more

Cancer Research 2020

Image
According to a new study men with breast cancer are more likely to die than their female counterparts, across all stages of disease.  The five-year mortality rate for men was 19% higher than for women. Additional studies are needed to identify the causes but any such studies would likely require international consortia because male breast cancer is so rare, accounting for less than 1% of cases. It is so rare, it would be extremely difficult for any single institute to recruit a sufficient number of patients for research. The study used 11 years of registry data from states 1.8 million female patients but only 16,025 male patients. About 85% of male breast cancer is ER-positive, a proportion that is higher than female breast cancer patients (75%) Join us at Cancer Research 2020 and present your research among global experts and know more about recent research.  click here for registration :  https://cancer.cmesociety.com/registration
Read more